Cell-based therapies for cardiac repair: A meeting report on scientific observations and European regulatory viewpoints

European Journal of Heart Failure

Volumn 18, Issue 2, 2016, Pages 133-141

  Schüssler Lenz, Martina ^a,b   Beuneu, Claire ^a,c   Menezes Ferreira, Margarida ^a,d   Jekerle, Veronika ^a   Bartunek, Jozef ^e   Chamuleau, Steven ^f   Celis, Patrick ^a   Doevendans, Pieter ^a,f   O'Donovan, Maura ^a,g   Hill, Jonathan ^h   Hystad, Marit ^a,i   Jovinge, Stefan ^j   Kyselovič, Ján ^k   Lipnik Stangelj, Metoda ^a,l   Maciulaitis, Romaldas ^a,m   Prasad, Krishna ^a,n   Samuel, Anthony ^a,o   Tenhunen, Olli ^a,p   Tonn, Torsten ^q   Rosano, Giuseppe ^a,r   Zeiher, Andreas ^s   Salmikangas, Paula ^a,p   more..

^a EUROPEAN MEDICINES AGENCY   (United Kingdom)

^b PAUL EHRLICH INSTITUT   (Germany)

^c Federal Agency for Medicines and Health Products Belgium   (Belgium)

^d INFARMED)   (Portugal)

^e OLV HOSPITAL   (Belgium)

^f UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^g Health Products Regulatory Authority   (Ireland)

^h NATIONAL HEALTH SERVICE   (United Kingdom)

ⁱ Norwegian Medicines Agency   (Norway)

^j DeVos Cardiovascular Research Program   (United States)

^k Physics and Informatics   (Slovakia)

^l UNIVERSITY OF LJUBLJANA   (Slovenia)

^m LITHUANIAN UNIVERSITY OF HEALTH SCIENCES   (Lithuania)

ⁿ MEDICINES AND HEALTHCARE PRODUCTS REGULATORY AGENCY   (United Kingdom)

^o MATER DEI HOSPITAL   (Malta)

^p Finnish Medicines Agency (FIMEA)   (Finland)

^q DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^r IRCCS SAN RAFFAELE PISANA   (Italy)

^s GOETHE UNIVERSITY   (Germany)

more..

Author keywords

Advanced therapy medicinal products; Cell based therapies for cardiac repair; Committee for Advanced Therapies; European regulatory aspects

Indexed keywords

ACUTE HEART INFARCTION; CARCINOGENICITY; CELL THERAPY; CLINICAL EFFECTIVENESS; CLINICAL OBSERVATION; CLINICAL RESEARCH; DIAGNOSTIC IMAGING; EUROPEAN; HEART FAILURE; HEART REPAIR; HUMAN; LAW; NONHUMAN; PRIORITY JOURNAL; REVIEW; TISSUE REPAIR; TREATMENT RESPONSE; ANIMAL; CELL TRANSPLANTATION; DISEASE MODEL; EUROPE; HEART; MYOCARDIAL INFARCTION; PHYSIOLOGY; PROCEDURES; REGENERATION;

ANIMALS; CELL TRANSPLANTATION; DISEASE MODELS, ANIMAL; EUROPE; HEART; HEART FAILURE; HUMANS; MYOCARDIAL INFARCTION; REGENERATION;

EID: 84958110035     PISSN: 13889842     EISSN: 18790844     Source Type: Journal    
DOI: 10.1002/ejhf.422     Document Type: Review

References (46)

1. WHO Fact sheet No. 310: The top 10 causes of death. http://www.who.int/mediacentre/factsheets/fs310/en/index.html (11 August 2015)
2. McManus DD, Gore J, Yarzebski J, Spencer F, Lessard D, Goldberg RJ,. Recent trends in the incidence, treatment, and outcomes of patients with STEMI and NSTEMI. Am J Med 2011; 124: 40-47.
3. Jernberg T, Johanson P, Held C, Svennblad B, Lindbäck J, Wallentin L,; SWEDEHEART/RIKS-HIA. Association between adoption of evidence-based treatment and survival for patients with ST-elevation myocardial infarction. JAMA 2011; 305: 1677-1684.
4. Fox KA, Carruthers KF, Dunbar DR, Graham C, Manning JR, De Raedt H, Buysschaert I, Lambrechts D, Van de Werf F,. Underestimated and underrecognized: the late consequences of acute coronary syndrome (GRACE UK-Belgian Study). Eur Heart J 2010; 31: 2755-2764.
5. Task Force, on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC), Steg PG, James SK, Atar D, Badano LP, Blömstrom-Lundqvist C, Borger MA, Di Mario C, Dickstein K, Ducrocq G, Fernandez-Aviles F, Gershlick AH, Giannuzzi P, Halvorsen S, Huber K, Juni P, Kastrati A, Knuuti J, Lenzen MJ, Mahaffey KW, Valgimigli M, van 't Hof A, Widimsky P, Zahger D,. ESC Guideline for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J 2012; 33: 2569-2619.
6. Orlic D, Kajstura J, Chimenti S, Jakoniuk I, Anderson SM, Li B, Pickel J, McKay R, Nadal-Ginard B, Bodine DM, Leri A, Anversa P,. Bone marrow cells regenerate infarcted myocardium. Nature 2001; 410: 701-705.
7. Menasché P., Cardiac cell therapy: lessons from clinical trials. J Mol Cell Cardiol 2011; 50: 258-265.
8. Assmus B, Schächinger V, Teupe C, Britten M, Lehmann R, Döbert N, Grünwald F, Aicher A, Urbich C, Martin H, Hoelzer D, Dimmeler S, Zeiher AM,. Transplantation of Progenitor Cells and Regeneration Enhancement in Acute Myocardial Infarction (TOPCARE-AMI). Circulation 2002, 106: 3009-3017.
9. Behfar A, Crespo-Diaz R, Terzic A, Gersh BJ,. Cell therapy for cardiac repair-lessons from clinical trials. Nat Rev Cardiol 2014; 11: 232-246.
10. European Medicines Agency. Guideline on human cell-based medicinal products (EMEA/CHMP/410869/2006). http://www.ema.europa.eu/docs/en-GB/document-library/Scientific-guideline/2009/09/WC500003894.pdf (11 August 2015)
11. Dimmeler S, Leri A,. Aging and disease as modifiers of efficacy of cell therapy. Circ Res 2008; 102: 1319-1330.
12. Assmus B, Tonn T, Seeger FH, Yoon CH, Leistner D, Klotsche J, Schächinger V, Seifried E, Zeiher AM, Dimmeler S,. Red blood cell contamination of the final cell product impairs the efficacy of autologous bone marrow mononuclear cell therapy. J Am Coll Cardiol 2010; 55: 1385-1394.
13. Seeger FH, Rasper T, Bönig H, Assmus B, Zeiher AM, Dimmeler S,. The challenges of autologous cell therapy: systemic anti-thrombotic therapies interfering with serum coagulation may disable autologous serum-containing cell products for therapeutical use. J Cardiovasc Transl Res 2014; 7: 644-650.
14. Seeger FH, Tonn T, Krzossok N, Zeiher AM, Dimmeler S,. Cell isolation procedures matter: a comparison of different isolation protocols of bone marrow mononuclear cells used for cell therapy in patients with acute myocardial infarction. Eur Heart J 2007; 28: 766-772.
15. Seeger FH, Rasper T, Fischer A, Muhly-Reinholz M, Hergenreider E, Leistner DM, Sommer K, Manavski Y, Henschler R, Chavakis E, Assmus B, Zeiher AM, Dimmeler S,. Heparin disrupts the CXCR4/SDF-1 axis and impairs the functional capacity of bone marrow-derived mononuclear cells used for cardiovascular repair. Circ Res 2012; 111: 854-862.
16. Aktas M, Radke TF, Strauer BE, Wernet P, Kogler G,. Separation of adult bone marrow mononuclear cells using the automated closed separation system Sepax. Cytotherapy 2008; 10: 203-211.
17. Traverse JH, Henry TD, Ellis SG, Pepine CJ, Willerson JT, Zhao DX, Forder JR, Byrne BJ, Hatzopoulos AK, Penn MS, Perin EC, Baran KW, Chambers J, Lambert C, Raveendran G, Simon DI, Vaughan DE, Simpson LM, Gee AP, Taylor DA, Cogle CR, Thomas JD, Silva GV, Jorgenson BC, Olson RE, Bowman S, Francescon J, Geither C, Handberg E, Smith DX, Baraniuk S, Piller LB, Loghin C, Aguilar D, Richman S, Zierold C, Bettencourt J, Sayre SL, Vojvodic RW, Skarlatos SI, Gordon DJ, Ebert RF, Kwak M, Moyé LA, Simari RD,; Cardiovascular Cell Therapy Research Network. Effect of intracoronary delivery of autologous bone marrow mononuclear cells 2 to 3 weeks following acute myocardial infarction on left ventricular function: the LateTIME randomized trial. JAMA 2011; 306: 2110-2119.
18. Schächinger V, Erbs S, Elsässer A, Haberbosch W, Hambrecht R, Hölschermann H, Yu J, Corti R, Mathey DG, Hamm CW, Süselbeck T, Assmus B, Tonn T, Dimmeler S, Zeiher AM,;, REPAIR-AMI Investigators,. Intracoronary bone marrow-derived progenitor cells in acute myocardial infarction. N Engl J Med 2006; 355: 1210-1221.
19. Makino S, Fukuda K, Miyoshi S, Konishi F, Kodama H, Pan J, Sano M, Takahashi T, Hori S, Abe H, Hata J, Umezawa A, Ogawa S,. Cardiomyocytes can be generated from marrow stromal cells in vitro. Clin Invest 1999; 103: 697-705.
20. Bartunek J, Behfar A, Dolatabadi D, Vanderheyden M, Ostojic M, Dens J, El Nakadi B, Banovic M, Beleslin B, Vrolix M, Legrand V, Vrints C, Vanoverschelde JL, Crespo-Diaz R, Homsy C, Tendera M, Waldman S, Wijns W, Terzic A,. Cardiopoietic stem cell therapy in heart failure: the C-CURE (Cardiopoietic stem Cell therapy in heart failURE) multicenter randomized trial with lineage-specified biologics. J Am Coll Cardiol 2013; 61: 2329-2338.
21. Barkholt L, Flory E, Jekerle V, Lucas-Samuel S, Ahnert P, Bisset L, Büscher D, Fibbe W, Foussat A, Kwa M, Lantz O, Mačiulaitis R, Palomäki T, Schneider CK, Sensebé L, Tachdjian G, Tarte K, Tosca L, Salmikangas P,. Risk of tumorigenicity in mesenchymal stromal cell-based therapies-bridging scientific observations and regulatory viewpoints. Cytotherapy 2013; 15: 753-759.
22. Burchfield JS, Dimmeler S,. Role of paracrine factors in stem and progenitor cell mediated cardiac repair and tissue fibrosis. Fibrogenesis Tissue Repair 2008; 1: 4.
23. Garbern JC, Lee RT,. Cardiac stem cell therapy and the promise of heart regeneration. Cell Stem Cell 2013; 12: 689-698.
24. Assmus B, Leistner DM, Schächinger V, Erbs S, Elsässer A, Haberbosch W, Hambrecht R, Sedding D, Yu J, Corti R, Mathey DG, Barth C, Mayer-Wehrstein C, Burck I, Sueselbeck T, Dill T, Hamm CW, Tonn T, Dimmeler S, Zeiher AM,; REPAIR-AMI Study Group. Long-term clinical outcome after intracoronary application of bone marrow-derived mononuclear cells for acute myocardial infarction: migratory capacity of administered cells determines event-free survival. Eur Heart J 2014; 35: 1275-1283.
25. Lafont A, Faxon D,. Why do animal models of post-angioplasty restenosis sometimes poorly predict the outcome of clinical trials? Cardiovasc Res 1998; 39: 50-59.
26. van der Spoel TI, Jansen of Lorkeers SJ, Agostoni P, van Belle E, Gyöngyösi M, Sluijter JP, Cramer MJ, Doevendans PA, Chamuleau SA,. Human relevance of pre-clinical studies in stem cell therapy: systematic review and meta-analysis of large animal models of ischaemic heart disease. Cardiovasc Res 2011; 91: 649-658.
27. van der Spoel TI, Vrijsen KR, Koudstaal S, Sluijter JP, Nijsen JF, de Jong HW, Hoefer IE, Cramer MJ, Doevendans PA, van Belle E, Chamuleau SA,. Transendocardial cell injection is not superior to intracoronary infusion in a porcine model of ischaemic cardiomyopathy: a study on delivery efficiency. J Cell Mol Med 2012; 16: 2768-2776.
28. Hudson W, Collins MC, deFreitas D, Sun YS, Muller-Borer B, Kypson AP,. Beating and arrested intramyocardial injections are associated with significant mechanical loss: implications for cardiac cell transplantation. J Surg Res 2007; 142: 263-267.
29. Sanganalmath SK, Bolli R,. Cell therapy for heart failure: a comprehensive overview of experimental and clinical studies, current challenges, and future directions. Circ Res 2013; 113: 810-834.
30. Unverferth DV, Fetters JK, Unverferth BJ, Leier CV, Magorien RD, Arn AR, Baker PB,. Human myocardial histologic characteristics in congestive heart failure. Circulation 1983; 68: 1194-1200.
31. Schmitto JD, Ortmann P, Vorkamp T, Heidrich F, Kolat P, Popov AF, Doerge H, Grossmann M, Seipelt R, Ramadori G, Schöndube AF,. Histological changes in a model of chronic heart failure induced by multiple sequential coronary microembolization in sheep. J Cardiovasc Surg (Torino) 2008; 49: 533-537.
32. Lara-Pezzi E, Menasché Ph, Trouvin JH, Badimõn L, Ioannidis JPA, Wu JC, Hill JA, Koch WJ, De Felice AF, de Waele P, Steenwinckel V, Hajjar RJ, Zeiher AM,. Guidelines for translational research in heart failure. J Cardiovasc Transl Res 2015; 8: 3-22
33. European Medicines Agency. Scientific Guidelines, Clinical efficacy and safety: Cardiovascular system. http://www.ema.europa.eu/ema/index.jsp?curlpages/regulation/general/general-content-000394.jspmidWC0b01ac0580034cef (11 August 2015)
34. Delewi R, Hirsch A, Tijssen JG, Schächinger V, Wojakowski W, Roncalli J, Aakhus S, Erbs S, Assmus B, Tendera M, Goekmen Turan R, Corti R, Henry T, Lemarchand P, Lunde K, Cao F, Huikuri HV, Sürder D, Simari RD, Janssens S, Wollert KC, Plewka M, Grajek S, Traverse JH, Zijlstra F, Piek JJ,. Impact of intracoronary bone marrow cell therapy on left ventricular function in the setting of ST-segment elevation myocardial infarction: a collaborative meta-analysis. Eur Heart J 2014; 35: 989-998.
35. Sürder D, Manka R, Lo Cicero V, Moccetti T, Rufibach K, Soncin S, Turchetto L, Radrizzani M, Astori G, Schwitter J, Erne P, Zuber M, Auf der Maur C, Jamshidi P, Gaemperli O, Windecker S, Moschovitis A, Wahl A, Bühler I, Wyss C, Kozerke S, Landmesser U, Lüscher TF, Corti R,. Intracoronary injection of bone marrow-derived mononuclear cells early or late after acute myocardial infarction: effects on global left ventricular function. Circulation 2013; 127: 1968-1979.
36. Clifford DM, Fisher SA, Brunskill SJ, Doree C, Mathur A, Watt S, Martin-Rendon E,. Stem cell treatment for acute myocardial infarction. Cochrane Database Syst Rev 2012; 2:CD006536.
37. Gyöngyösi M, Wojakowski W, Lemarchand P, Lunde K, Tendera M, Bartunek J, Marban E, Assmus B, Henry TD, Traverse JH, Moyé LA, Sürder D, Corti R, Huikuri H, Miettinen J, Wöhrle J, Obradovic S, Roncalli J, Malliaras K, Pokushalov E, Romanov A, Kastrup J, Bergmann MW, Atsma DE, Diederichsen A, Edes I, Benedek I, Benedek T, Pejkov H, Nyolczas N, Pavo N, Bergler-Klein J, Pavo IJ, Sylven C, Berti S, Navarese EP, Maurer G,;, ACCRUE Investigators,. Meta-Analysis of Cell-based CaRdiac stUdiEs (ACCRUE) in patients with acute myocardial infarction based on individual patient data. Circ Res 2015; 116: 1346-1360.
38. Costanzo MR, Augustine S, Bourge R, Bristow M, O'Connell JB, Driscoll D, Rose E,. Selection and treatment of candidates for heart transplantation. A statement for health professionals from the Committee on Heart Failure and Cardiac Transplantation of the Council on Clinical Cardiology, American Heart Association. Circulation 1995; 92: 3593-3612.
39. Westenbrink BD, Voors AA, de Boer RA, Schuringa JJ, Klinkenberg T, van der Harst P, Vellenga E, van Veldhuisen DJ, van Gilst WH,. Bone marrow dysfunction in chronic heart failure patients. Eur J Heart Fail 2010; 12: 676-684.
40. Assmus B, Walter DH, Seeger FH, Leistner DM, Steiner J, Ziegler I, Lutz A, Khaled W, Klotsche J, Tonn T, Dimmeler S, Zeiher AM,. Effect of shock wave-facilitated intracoronary cell therapy on LVEF in patients with chronic heart failure: the CELLWAVE randomized clinical trial. JAMA 2013; 309: 1622-1631.
41. Kang WJ1, Kang HJ, Kim HS, Chung JK, Lee MC, Lee DS,. Tissue distribution of 18 F-FDG-labeled peripheral hematopoietic stem cells after intracoronary administration in patients with myocardial infarction. J Nucl Med 2006; 47: 1295-1301.
42. Putzeist M, Mantel-Teeuwisse AK, Aronsson B, Rowland M, Gispen-de Wied CC, Vamvakas S, Hoes AW, Leufkens HG, Eichler HG,. Factors influencing non-approval of new drugs in Europe. Nat Rev Drug Discov 2012; 11 (12): 903-904.
43. European Parliament and Council: DIRECTIVE 2001/20/EC OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL. http://eurlex.europa.eu/LexUriServ/LexUriServ.do?uriOJ:L:2001:121:0034:0044:en:PDF (11 August 2015)
44. European Medicines Agency: Guideline on risk-based approach according to Annex I, Part IV of Directive 2001/83/EC applied to Advanced Therapy Medicinal Products (EMA/CAT/CPWP/686637/2011). http://www.ema.europa.eu/docs/en-GB/document-library/Scientific-guideline/2013/03/WC500139748.pdf (11 August 2015)
45. European Commission: COMMISSION DIRECTIVE 2009/120/EC. http://ec.europa.eu/health/files/eudralex/vol1/dir-2009-120/dir-2009-120-en.pdf (11 August 2015)
46. BAMI. The Effect of Intracoronary Reinfusion of Bone Marrow-derived Mononuclear Cells(BM-MNC) on All Cause Mortality in Acute Myocardial Infarction. http://clinicaltrials.gov/show/NCT01569178 (11 August 2015)